Abstract
Glutamate is the major excitatory neurotransmitter in the brain. Amongst ionotropic receptors responding to glutamate, the AMPA subtype has been considered as essential for the fast excitatory neurotransmission in the central nervous system and the expression and maintenance of long-term potentiation. As glutamate is known to be involved in many neurological and psychiatric disorders, AMPA receptors seem to represent interesting targets to develop therapeutic drugs. Hence, the enhancement of AMPA signals is an approach currently investigated for the management of Alzheimers disease, schizophrenia or mood disorders. In particular, many efforts are being conducted in the development of AMPA positive allosteric modulators (“potentiators”), which alter the rate of receptor desensitization. The major chemical families developed as AMPA potentiators are aniracetam derivatives, cyclothiazide derivatives and biarylpropylsulfonamides derivatives.
Keywords: Glutamate receptors, AMPA potentiator, AMPA positive allosteric modulator, cognitive enhancers, mood disorders treatment
Recent Patents on CNS Drug Discovery (Discontinued)
Title: In Search of Novel AMPA Potentiators
Volume: 1 Issue: 3
Author(s): Pierre Francotte, Pascal de Tullio, Pierre Fraikin, Stephane Counerotte, Eric Goffin and Bernard Pirotte
Affiliation:
Keywords: Glutamate receptors, AMPA potentiator, AMPA positive allosteric modulator, cognitive enhancers, mood disorders treatment
Abstract: Glutamate is the major excitatory neurotransmitter in the brain. Amongst ionotropic receptors responding to glutamate, the AMPA subtype has been considered as essential for the fast excitatory neurotransmission in the central nervous system and the expression and maintenance of long-term potentiation. As glutamate is known to be involved in many neurological and psychiatric disorders, AMPA receptors seem to represent interesting targets to develop therapeutic drugs. Hence, the enhancement of AMPA signals is an approach currently investigated for the management of Alzheimers disease, schizophrenia or mood disorders. In particular, many efforts are being conducted in the development of AMPA positive allosteric modulators (“potentiators”), which alter the rate of receptor desensitization. The major chemical families developed as AMPA potentiators are aniracetam derivatives, cyclothiazide derivatives and biarylpropylsulfonamides derivatives.
Export Options
About this article
Cite this article as:
Francotte Pierre, de Tullio Pascal, Fraikin Pierre, Counerotte Stephane, Goffin Eric and Pirotte Bernard, In Search of Novel AMPA Potentiators, Recent Patents on CNS Drug Discovery (Discontinued) 2006; 1 (3) . https://dx.doi.org/10.2174/157488906778773661
DOI https://dx.doi.org/10.2174/157488906778773661 |
Print ISSN 1574-8898 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3954 |
Related Books
Related Articles
-
Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs
Current Medicinal Chemistry Potential Health Benefits of Passion Fruit Peel Flour
The Natural Products Journal Histamine H3 Receptor Function and Ligands: Recent Developments
Mini-Reviews in Medicinal Chemistry Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Physiology and Pathophysiology of Na+/H+ Exchange Isoform 1 in the Central Nervous System
Current Neurovascular Research Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry The Progress of Epilepsy after Stroke
Current Neuropharmacology Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Stereoselective Interactions Between Local Anesthetics and Cardiac K+ Channels
Drug Design Reviews - Online (Discontinued) Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Design and Evaluation of Semicarbazones and Thiosemicarbazones as Novel Anticonvulsants
Central Nervous System Agents in Medicinal Chemistry Familial Mediterranean Fever
Current Rheumatology Reviews Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders
Current Neuropharmacology Screening of Some Novel 4, 5 Disubstituted 1, 2, 4-Triazole-3-thiones for Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model
Current Neurovascular Research